Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Subscribe to see Neuphoria Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Neuphoria Therapeutics Inc. is a biotech company headquartered in Burlington, United States. It is publicly listed (NEUP) with a market capitalisation of $21.2M. Xcout tracks 16 named people at Neuphoria Therapeutics Inc., including Spyridon Papapetropoulos (Interim CEO & Executive Director).
10 more named people on record for Neuphoria Therapeutics Inc., with roles, board committees and tenure — see the full roster →
2 corporate events on record, with sources — see the full timeline →
A few of Neuphoria Therapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Delix Therapeutics is a privately held biopharmaceutical company headquartered in Boston, Massachusetts, focused on transforming the treatment of brain health through neuroscience.
Neurogastrx, Inc. is a pharmaceutical manufacturing company founded in 2012. Its main headquarters is located at 500 Unicorn Park Drive in Woburn, Massachusetts, where it is passionate about developing therapies to advance treatment.
Myrobalan Therapeutics is a pre-clinical biotechnology company headquartered in Medford, Massachusetts, focused on developing oral small molecule therapies for central nervous system and neurodegenerative diseases. The company targets novel mechanisms to create neurorestorative treatments for CNS disorders.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.